Literature DB >> 16370333

The potential use of myogenic stem cells in regenerative medicine.

G Grenier1, M A Rudnicki.   

Abstract

More than a century after the initial description of muscular dystrophy, no curative treatment is currently available. To date, clinical trials with myogenic stem cell transplantation have met with only modest success. There are multiple factors behind these failures, yet they provide powerful insights for improvement. In this chapter, we review the different myogenic stem cell populations that have been reported to be potential vectors for the treatment of myopathies in a context of regenerative medicine.

Entities:  

Mesh:

Year:  2006        PMID: 16370333

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  1 in total

1.  The muscle regulatory transcription factor MyoD participates with p53 to directly increase the expression of the pro-apoptotic Bcl2 family member PUMA.

Authors:  Terri J Harford; Greg Kliment; Girish C Shukla; Crystal M Weyman
Journal:  Apoptosis       Date:  2017-12       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.